Dr Mohamed Saad received his Bachelor of Pharmacy and Master of Biochemistry from Alexandria University, Egypt. He then received the Monash International Postgraduate Research Scholarship (MIPRS) to pursue his PhD studies at the Hudson Institute of Medical Research, Monash University, Australia, under the supervisor of Professor Brendan Jenkins. In 2019, he completed his PhD research and is now working as a Postdoctoral Scientist with Professor Jenkins.
During his PhD, Dr Saad identified the ADAM17 protease as a key therapeutic target to tackle non-small cell lung cancer. His current work focuses on identifying the role of ADAM17 in inflammatory conditions including emphysema and pancreatitis. Dr Saad was awarded best poster prize at the 31st Lorne Cancer Conference for this PhD studies and received a Hudson Travel Award in 2019 to present his work and meet with collaborators at the Cytokines 2019 conference in Vienna, Austria.
- Saad MI, Alhayyani S, McLeod L, Yu L, Alanazi M, DeswaerteV, TangK,Jarade T, Smith JA, Prodanovic Z, Tate MD, BalicJJ, Watkins DN, Cain JE, Bozinovski S, Algar E, KohmotoT, Ebi H,Ferlin W, Garbers C, Ruwanpura S, Sagi I, Rose-John S, Jenkins BJ (2019) ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer. EMBO Mol. Med 2019:e9976.
Saad M, Ruwanpura SM (2018) Tissue Processing for Stereological Analyses of Lung Structure in Chronic Obstructive Pulmonary Disease. In: Inflammation & Cancer, Jenkins BJ ed. New York: Methods in Molecular Biology. Vol 1725, pp 155-162.
- Saad MI, Abdelkhalek TM, Saleh MM, Kamel MA, Youssef M, Tawfik SH, Dominguez H (2015) Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells. Endocrine 50(3):537-67.